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Ligand efficiency has proven to be a valuable concept for opti-
mization of leads in the early stages of drug design. Taking this
one step further, group efficiency (GE) evaluates the binding
efficiency of each appendage of a molecule, further fine-tuning
the drug design process. Here, GE analysis is used to systemati-
cally improve the potency of inhibitors of Mycobacterium tuber-
culosis pantothenate synthetase, an important target in tuber-
culosis therapy. Binding efficiencies were found to be distribut-
ed unevenly within a lead molecule derived using a fragment-
based approach. Substitution of the less efficient parts of the
molecule allowed systematic development of more potent
compounds. This method of dissecting and analyzing different
groups within a molecule offers a rational and general way of
carrying out lead optimization, with potential broad applica-
tion within drug discovery.
The concept of ligand efficiency (LE)[1–3] has been used as an
important guiding principle for lead optimization in early stage
drug design. Subsequently, the idea of group efficiency (GE)[4]
was proposed, and this has been applied to identify hotpots
on proteins and to analyze parts of a ligand that make impor-
tant contributions to binding.[5–9] Herein, we describe the use
of GE to optimize a fragment-derived inhibitor of Mycobacteri-
um tuberculosis pantothenate synthetase, an attractive target
for developing new drugs against tuberculosis.[10–12]
Pantothenate synthetase catalyzes the ATP-dependent for-
mation of an amide bond between pantoate and b-ala-
nine.[11–12] We have previously reported the identification of
fragments 1 and 2 (see Schemes 1 and 2) from biophysical
screens using thermal shift and NMR methods.[13–14] The step-
wise growing of indole fragment 1 led to the generation of
lead compound 5 (Scheme 1; see also, Figure S1 in the Sup-
porting Information).[13] In a parallel study, linking of fragments
1 and 2 afforded compounds 6–9 (Scheme 2; see also, Fig-
ure S2 in the Supporting Infor-
mation).[13,15] Both fragment
growing and linking approaches
rapidly led to relatively potent
inhibitors against pantothenate
synthetase (5 : KD=1.5 mm and 9 :
KD=0.9 mm).
Based solely on the KD values
and LE data obtained for com-
pounds 5 and 8, it was not obvi-
ous how to identify areas and
vectors for further optimization
of the compounds. Therefore, in an effort to improve binding
potency while maintaining LE,[16–17] a GE approach was used to
analyze compounds 5 and 8. Following a similar Free–Wilson
analysis[18] as proposed by Saxty and co-workers,[6] compounds
5 and 8 were dissected into component parts, and the binding
contributions (DDG) from these individual building blocks cal-
culated. These data are summarized in Figure 1 (for detailed
calculations of GE, see the section entitled “Calculations for GE
analysis” in the Supporting Information). This GE analysis
around 5 and 8 quickly revealed inefficient binding compo-
nents within the molecules, suggesting straightforward ap-
proaches to fragment modifications without indiscriminately
increasing the inhibitor size.
As shown in Figure 1, the majority of the binding energy
resides in the original indole fragment (GE=0.75). A similar
observation has been observed in other fragment elaboration
Scheme 1. A fragment-growing approach applied against Mycobacterium tuberculosis pantothenate synthetase,
generating lead compound 5.
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strategies[6] and is mainly due to the high intrinsic binding en-
ergies required for fragments to be detected (DG=4.2 kcal
mol¢1[19] is added to the binding of indole group 1 to compen-
sate for the free energy associated with loss of fragment rigid-
body entropy during binding).
Similarly, the charged acetate side chain in both 5 and 8
also contributes significantly to the overall binding, possessing
high GE values of 0.43 and 0.35, respectively. Conversely, GE
analysis highlights the limited contribution to binding of the
acyl sulfonamide, methyl pyridine and the benzofuran groups,
all of which have calculated GE values of 0.16–0.17 (the GE of
the sulfamoyl group is based on the N-(methylsulfonyl)acet-
amide group).
Previous work on fragment growing and linking[13] have
shown that the acyl sulfonamide groups not only contributed
to additional binding energy by forming additional hydrogen
bonds between the sulfone oxygen and both the backbone
amide of Met40 and the side
chain of His47, but more impor-
tantly also served as an effective
functional group for directing
the correct vectors towards both
the P1 and P2 pockets without
clashing with the side of the
active site formed by Met40 (Fig-
ure S4 in the Supporting Infor-
mation). Based on these observa-
tions, the initial optimization
strategy was focused on replace-
ment of the methyl pyridine and
the benzofuran groups rather
than the acyl sulfonamide linker
in both compounds 5 and 8.
Compounds were designed
with the objective of optimizing
interactions at the P1 or P2 sites of panthothenate synthetase.
Consequently, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
(EDCI)-mediated coupling reactions were employed to gener-
ate a series of indole acyl sulfonamide compounds (10–19 ; the
syntheses are described in the Supporting Information).
The binding of compounds 10–19 against M. tuberculosis
pantothenate synthetase was determined by isothermal titra-
tion calorimetry (ITC), and the structure–affinity relationship
(SAR) results are summarized in Table 1; ITC binding data for all
compounds are presented in the Supporting Information). Re-
placing the methyl pyridine/benzofuran groups in 5 and 8
generated a series of sub-micromolar inhibitors (10–14).The
substitution of the methyl pyridine ring (5) by a more electron-
rich toluene group (10 : KD=340 nm, LE=0.32) resulted in ap-
proximately a fourfold improvement in affinity towards the
enzyme. Compound 10 was the most ligand efficient com-
pound tested. The GE value for the toluene group in 10 is
Scheme 2. A fragment-linking approach applied against Mycobacterium tuberculosis pantothenate synthetase gen-
erating lead compounds 6–9. (X–Y–Z represents the approximate three-atom length of the linker.)
Figure 1. A) Group efficiency (GE) analysis of compound 5 estimates the contributions of the binding efficiencies from different functional groups and quickly re-
veals inefficient binding groups in the molecule for further optimization of potency. B) A similar GE analysis applied towards compound 8. *DDG=DG¢DGrigid,
DGrigid=4.2 kcalmol
¢1.[19] The cross-sectional view of the X-ray crystal structure of the active pocket of pantothenate synthetase is shown in green with inhibitors
5 and 8 bound. (The cross-sectional view was generated by removing residues from one half of the active pocket of pantothenate synthetase using the DS visu-
alizer software. The surface on the other half of the protein was generated using PyMol v.0.99[20]). DG values of the compounds were determined from titration
experiments using ITC. The GE value is subsequently calculated by dividing the DG contribution from each group by the number of heavy atoms in the group.
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0.35—a marked improvement over the GE values of 0.17 and
0.16 for the methyl pyridine and benzofuran groups in 5 and
8, respectively.
Gratifyingly, the addition of a bulkier and more electronega-
tive trifluromethyl group to the indole sulfonamide core gave
rise to 11, the most potent compound of this series (KD=
200 nm, LE=0.30, GE=0.27). Likewise, the installation of hy-
drophobic and larger groups like tert-butylbenzene (12) and
naphthalene (13) gave rise to compounds that bind to pan-
tothenate synthetase with improved affinity (KD=460 nm and
610 nm, respectively) compared with parent compounds 5 and
8. Interestingly, the more hydrophilic indole acyl sulfonamides
15–19 (cLogP=1.0–3.2) bind with lower affinities (KD=2–
17 mm) compared with more lipophilic compounds 10–14
(cLogP=3.6–5.0).
This step of the optimization process was achieved in large
part based on GE and SAR analysis without much consider-
ation of structure. However, it did assume that the new com-
pounds bind at the active site of pantothenate synthetase in
a similar way to the original lead compounds, 5 and 8. In order
to establish this, the structures of the four most potent inhibi-
tors (10–13) bound to the enzyme were solved using protein
X-ray crystallography (Figure 2).
The X-ray crystal structures of 10–13 bound to pantothenate
synthetase show binding at the active site, with a conserved
binding mode for the indole sulfonamide fragment core. Less
obviously, the substituted groups on all four compounds were
seen to bind in the P1 pocket of the enzyme (see Figure 1B).
The P1 pocket binds the alkyl groups of the pantoate substrate
and is primarily lipophilic, surrounded by the hydrophobic resi-
dues Pro38, Met40, Val 143, Leu146 and Phe157 (Figure S5 in
the Supporting Information). In contrast, the P2 site binds the
phosphates of ATP and is relatively hydrophilic. As can be seen
in Figure 2, the binding orientations of the added groups are
all similar, and no new hydrogen bonds are formed. The de-
tailed binding interactions of the most potent compound (11)
with the P1 pocket residues are shown in Figure S5 in the Sup-
porting Information. In addition to binding assays and X-ray
crystallography studies, an inhibition study was carried out
that demonstrated that compound 11 inhibits pantothenate
synthetase with an IC50 value of 5.7 mm (see the Supporting
Information).
Table 1. Indole sulfonamide analogues 10–19 derived from SAR considerations around 5 and 8.
Compd R KD [mm]
[a] LE (GE)[b] cLogP[c] Compd R KD [mm]
[a] LE (GE)[b] cLogP[c]
5 1.5 0.28 (0.17) 3.0 14 0.80 0.25 (0.15) 4.2
8 1.8 0.26 (0.16) 3.7 15 3.5 0.28 (0.17) 1.4
10 0.34 0.32 (0.35) 3.6 16 17 0.22 (0.01) 1.0
11 0.2 0.30 (0.27) 4.4 17 4 0.25 (0.17) 1.6
12 0.46 0.28 (0.22) 5.0 18 6 0.23 (0.07) 2.2
13 0.61 0.27 (0.21) 4.3 19 2 0.27 (0.17) 3.2
[a] KD values were determined from titration experiments using ITC. [b] Ligand efficiency (LE) and group efficiency (GE) were calculated based on DG
values derived from ITC and the number of heavy atoms associated with the corresponding groups/compounds. [c] cLogP values were derived from
ChemDraw.
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The structural data on compounds 10–13 provided the im-
petus for further elaboration of the series, with a view to
making a compound that probes more deeply into the P1 site.
It was rationalized that the introduction of a methylene group
between the aromatic and sulfonyl groups should allow the ar-
omatic group to slide below Met40 and push a para substitu-
ent to the back of the P1 pocket
(Figure 3; for detailed binding
interactions of 11 with the P1
pocket, see also Figure S5 in the
Supporting Information). To test
this hypothesis, compound 20
was synthesized, using a trifluor-
omethyl-substituted benzylsulfo-
namide as a new coupling sub-
strate.
The X-ray crystal structure of
20 bound to M. tuberculosis pan-
tothenate synthetase (Figure 3)
showed the hoped for binding
with the trifluoromethyl group
picking up favorable hydropho-
bic interactions with Val139,
Val 142 and Val143. Compound
20 was shown to inhibit the en-
zymatic reaction with a signifi-
cantly improved IC50 value of
250 nm as compared with 11.
Furthermore, a cell-based assay
against M. tuberculosis showed
on-target inhibitory activity
leading to cell death.[21]
As the use of fragment-based
methods expands, the need for
subsequent lead optimization of
fragment-derived compounds
becomes increasingly important. The work presented here
demonstrates the use of GE analysis to critically and thorough-
ly examine the binding distribution of a lead compound and il-
lustrates the practicality of applying GE analysis to modify
parts of a molecule that are not making efficient contributions
to binding. In this case, it led to the generation of a relatively
Figure 2. The X-ray crystal structures of four of the most potent compounds (10–13) bound to Mycobacterium tuberculosis pantothenate synthetase (PDB
code: 4MQ6, 4MUE, 4MUF, 4MUL, respectively). The ligands are shown as sticks with carbon atoms in light blue, nitrogen atoms in dark blue, oxygen atoms
in red, and sulfur atoms in yellow. The cross-sectional area of the active pocket of pantothenate synthetase is shown in green. All figures were generated and
rendered with PyMOL v.0.99.[20]
Figure 3. Compound 20 was found to inhibit Mycobacterium tuberculosis pantothenate synthetase with an IC50
value of 253 nm (LE=0.28 based on IC50). The X-ray crystal structure of 20 bound to the active pocket of the
enzyme shows the hydrophobic trifluoromethyl benzene group buried deep in the P1 site, surrounded by lipo-
philic residues Gln72, Val142 and Val143 (PDB code: 4MUK).
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potent and bactericidal inhibitor of M. tuberculosis pantothen-
ate synthetase.
Experimental Section
Syntheses and characterization of organic molecules, biochemical,
X-ray crystallography and isothermal titration calorimetry methods
are described in the Supporting Information. Additionally, NMR
spectra related to this publication are also available at the Universi-
ty of Cambridge data repository (www.repository.cam.ac.uk/
handle/1810/249084).
Protein X-ray crystallography structures of compounds 10–13 and
20 bound to M. tuberculosis pantothenate synthetase are available
via the RCSB Protein Data Bank via PDB codes: 4MQ6 (10), 4MUE
(11), 4MUF (12), 4MUL (13), and 4MUK (20).
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